Coherus Stock Soars on Wall Street Radar: 585% Upside Potential
Guggenheim rates Coherus Oncology Buy with $12 target vs $1.75 now, seeing big upside in cancer drug pipeline but high risk.
/ 79 items
#XY Analyst Up/Down↓
Why Oppenheimer is Bullish on Tiny Biotech Aprea Therapeutics
Oppenheimer backs Aprea with $5 target. Its cancer drug shows early promise, and low valuation offers big upside potential.
Wedbush Ignites Pyxis Oncology with Bullish Rating — 215% Upside Ahead?
Wedbush rates Pyxis “Outperform” with $6 target vs $1.90. Early cancer drug data promising but risky biotech with funding needs.
ITK Pipeline Spotlight: Guggenheim Initiates Buy on Aclaris Therapeutics
Guggenheim rates ACRS Buy, $12 target vs $4.50 now; skin/immune drugs, trials ahead, big upside if results are good.
Citizens Bullish on Biomea: Could This Pill Actually Fix Diabetes?
Biomea is testing a new diabetes pill that may fix insulin cells. Early results look strong, with big growth potential but high risk.
“Game-Changer” Breast Cancer Drug News Triggers H.C. Wainwright Upgrade for Celcuity
Celcuity’s drug showed strong results in breast cancer, boosting survival and raising hopes it could become a new standard treatment.